PFE Pfizer Inc.

41.9
+0.04  (+0%)
Previous Close 41.85
Open 41.81
Price To Book 3.67
Market Cap 232592861677
Shares 5,551,804,790
Volume 9,930,829
Short Ratio 5.42
Av. Daily Volume 26,479,888

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 initiation announced December 13, 2017. Data due 2019.
PF-04965842 - abrocitinib
Moderate-to-severe atopic dermatitis (AD)
Approval announced December 13, 2017.
IXIFI
Remicade (infliximab) biosimilar
Phase 3 data released November 28, 2017 - primary endpoint not met.
Avelumab
Gastric cancer
Approval announced October 12, 2017.
LYRICA (pregabalin)
Postherpetic neuralgia (PHN)
Advisory Committee Meeting held November 7, 2017. No votes cast.
Staphylococcus aureus vaccine
Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
FDA approval announced November 2, 2018.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 3 trial initiated March 2017. Data due 2020.
PF-06425090
C. difficile Infection
Phase 3 trial met primary endpoint - December 20, 2018.
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 ongoing. Primary completion date estimated mid-2020.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
FDA approval announced July 13, 2018.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
Approval announced May 30, 2018.
Xeljanz
Ulcerative colitis
Approval announced December 14, 2017.
Xeljanz
Psoriatic arthritis
FDA Approval announced October 16, 2018.
Talazoparib
BRCA-mutated breast cancer
Approval announced 16 November, 2017.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Approval announced December 19, 2017.
BOSULIF (BOSUTINIB)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Safety trial data due 2019.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 data due late-2Q 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Approved Sept 10 2014
XTANDI
Cancer - mCRPC who have not received chemotherapy
PDUFA date November 2019. Exact date not provided. Estimate November 14, 2019.
Tafamidis (tafamidis free acid form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA Approval announced September 27, 2018.
Dacomitinib
Non-small cell lung cancer (NSCLC)
BsUFA date 3Q 2019.
PF-05280586 (Biosimilar to Rituxan/ MabThera)
CD20-positive, low tumor burden, follicular lymphoma
Phase 3 trial discontinued due to futility.
INLYTA (axitinib)
Recurrent renal cell carcinoma (RCC)
Phase 1b initiation announced April 12, 2018. Early data due 1H 2019.
PF-06939926
Duchenne muscular dystrophy (DMD)
Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously).
IBRANCE - PALOMA-3
Breast cancer
Phase 3 presentation at ASCO June 2018.
IBRANCE (palbociclib)
Head and neck squamous cell carcinoma
FDA approval announced November 21, 2018.
Glasdegib
Acute myeloid leukemia (AML)
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 2 development terminated due to lack of efficacy.
Domagrozumab
Duchenne muscular dystrophy (DMD)
PDUFA date under priority review June 2019. Exact date not provided.
BAVENCIO (avelumab) and INLYTA (axitinib)
Renal cell carcinoma (RCC)
PDUFA date under priority review June 20, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
BsUFA date 2Q 2019.
PF-06439535
Biosimilar bevacizumab
FDA Approval March 11, 2019.
PF-05280014 TRAZIMERA
Herceptin biosimilar
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met.
Tanezumab
Osteoarthritis
Phase 3 trial to be terminated due to lack of efficacy.
Avelumab - JAVELIN Ovarian 100
Ovarian cancer
Phase 2b/3 initiation announced January 3, 2018.
PF-06651600
Alopecia areata
PDUFA date under priority review July 2019. Exact date not provided. Estimate July 14, 2019.
Tafamidis (tafamidis meglumine form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)

Latest News

  1. S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion
  2. Final Trades: Verizon, XPO, Pfizer, Alphabet and BB&T
  3. Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
  4. Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
  5. Boeing's Lesson About The Dow
  6. Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
  7. Pfizer buys stake in French gene company in deal worth up to $636M
  8. Invest in America’s Rising Healthcare Costs With These Stocks
  9. Pfizer buys stake in French gene therapy firm Vivet
  10. Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
  11. Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
  12. Glaxo Presents Encouraging Data on Endometrial Cancer Drug
  13. Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million
  14. Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak
  15. The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company
  16. Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million
  17. Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics
  18. 5 High-Quality, High-Yielding Stocks
  19. Stocks - FedEx, Google Fall in Pre-market; General Mills Jumps
  20. Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer